All Trials

Phase II Trial of Lenvatinib-Pembrolizumab Maintenance Therapy in Patients With Advanced Unresectable Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable, advanced pancreatic ductal adenocarcinoma who have achieved at least stable disease after ≥16 weeks of first- or second-line chemotherapy receive maintenance pembrolizumab (anti–PD-1) plus lenvatinib (oral multikinase inhibitor of VEGFR/FGFR/PDGFR/RET/KIT). Single-arm maintenance approach aims to prolong disease control; excludes prior checkpoint inhibitor therapy and requires ECOG 0–1 and adequate organ function.

ClinicalTrials.gov ID: NCT04887805

Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic pancreatic adenocarcinoma are subtyped by PurIST: basal-like tumors receive bi-weekly gemcitabine/nab‑paclitaxel plus low‑dose erlotinib (EGFR TKI) with dose optimization, while classical tumors receive standard oxaliplatin-based triplet chemotherapy (FOLFIRINOX or NALIRIFOX). Eligible patients have ECOG 0–1, measurable disease, no prior systemic therapy for PDAC, and tissue available for PurIST testing.

ClinicalTrials.gov ID: NCT06483555

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with previously treated locally advanced/metastatic pancreatic adenocarcinoma (post–gemcitabine/nab-paclitaxel or FOLFIRINOX; ECOG 0–2) receive oral azeliragon, a small‑molecule RAGE antagonist targeting inflammatory signaling (HMGB1/S100/AGEs), using a loading then maintenance dosing schedule in a dose‑escalation, single‑arm study. Key exclusions include ECOG >2, short life expectancy, strong CYP2C8 inhibitors, malabsorption, and significant comorbidities.

ClinicalTrials.gov ID: NCT05766748

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with well/moderately differentiated, metastatic, unresectable, somatostatin receptor–positive pancreatic NETs (ECOG 0–2) who are PRRT- and sunitinib-naïve, allowing prior SSA and up to one prior systemic therapy. Investigates combination of lutetium Lu 177 dotatate PRRT and sunitinib (multi–TKI targeting VEGFR/PDGFR) to define safety/MTD and assess preliminary efficacy.

ClinicalTrials.gov ID: NCT05687123

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with biopsy-proven locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (ECOG 0–2, minimal prior therapy allowed) receive standard multiagent chemotherapy plus endoscopic ultrasound–guided radiofrequency ablation of the primary tumor and pembrolizumab, an anti–PD-1 antibody. Aims to test whether local ablation can enhance immune priming and systemic activity of PD-1 blockade alongside chemotherapy.

ClinicalTrials.gov ID: NCT06831136

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable or metastatic hepatocellular carcinoma or biliary tract cancer (now BTC only) who are immunotherapy‑naïve receive durvalumab (PD‑L1 inhibitor) plus tremelimumab (CTLA‑4 inhibitor) with hypofractionated radiation to one lesion (8 Gy × 3) during cycle 2, then durvalumab maintenance. Prior therapy requirements vary by histology; patients must have a second measurable non-irradiated lesion and meet liver function and viral hepatitis control criteria.

ClinicalTrials.gov ID: NCT03482102

An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) with PVE Alone in Patients with Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with colorectal liver metastases and insufficient future liver remnant (<30%, or <40% post-chemotherapy), including select patients with intact primaries and resectable/ablatable extrahepatic disease, are randomized to standard portal vein embolization versus combined portal plus hepatic vein embolization to induce FLR hypertrophy prior to hepatectomy. The trial compares rates and speed of achieving resectable FLR and downstream survival and perioperative outcomes.

ClinicalTrials.gov ID: NCT05428735

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/metastatic, GPC3-positive HCC after ≥2 prior systemic therapies receive lymphodepleting cyclophosphamide/fludarabine followed by ECT204, an autologous ARTEMIS AbTCR T-cell therapy targeting glypican-3 designed to retain cytotoxicity with reduced cytokine release versus CAR T cells. Phase 2 includes cohorts of ECT204 at the RP2D with or without regorafenib pre-treatment to assess impact on safety and efficacy.

ClinicalTrials.gov ID: NCT04864054

A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/advanced HCC (ECOG 0–1, Child-Pugh A) who progressed on first-line atezolizumab plus bevacizumab are randomized to cabozantinib or lenvatinib with or without atezolizumab. Atezolizumab is an anti–PD-L1 antibody restoring T-cell activity; cabozantinib and lenvatinib are VEGFR-targeting multi-kinase inhibitors.

ClinicalTrials.gov ID: NCT05168163

Phase 2, Single Arm Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-A*02:01–positive metastatic uveal melanoma predominantly confined to the liver receive Y-90 transarterial radioembolization followed by weekly tebentafusp. Tebentafusp is a bispecific gp100–HLA-A*02:01–targeted TCR/anti-CD3 ImmTAC that redirects T cells to melanoma cells; key exclusions include large (>8 cm) dominant liver lesions, significant hepatic dysfunction, vascular shunting precluding TARE, and active CNS metastases requiring steroids.

ClinicalTrials.gov ID: NCT06627244